Inspyr Therapeutics Further Strengthens Global Intellectual Property

Author's Avatar
Feb 18, 2021
Article's Main Image

WESTLAKE VILLAGE, CA / ACCESSWIRE / February 18, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces additional expansion of its global intellectual property portfolio of adenosine receptor antagonists in China, Eurasia, and Israel.